Skip to content

LSD: all studies

Page 152 of 282: studies 1,511 to 1,520 of 2,815, newest first. Back to the LSD overview

Research

Classic psychedelic and cannabis use among U.S. cancer survivors aged ≥ 50 years: nationally representative estimates by cancer type/site.

Cancer causes & control : CCC April 22, 2026 Amrit Baral, Yue Pan, Wayway M. Hlaing et al.

To examine the prevalence of lifetime ("ever") cannabis and classic psychedelic use, and their co-use among U.S. adults aged ≥ 50 years with versus without a lifetime history of cancer, and to describe variation by cancer type/site among survivors. We analyzed pooled 2015-2019 and 2021-2022 National Survey on Drug Use and Health (NSDUH) data of U.S. adults aged ≥ 50 years (Unweighted; n =...

Psychedelics and Autism Therapy: A Review of Current Research and Future Directions

Current Issues in Molecular Biology April 18, 2026 Christopher S. Gondi, Manu Gnanamony, Tarun P. Gondi et al.

Autism Spectrum Disorder (ASD) is a lifelong condition marked by challenges in social communication and repetitive behaviors. Current treatments, primarily behavioral therapies, often fail to address the core symptoms. Recent research has explored the potential of psychedelics, such as LSD, psilocybin, and MDMA, as a new therapeutic approach. While these substances primarily modulate the...

DOI: 10.3390/cimb48040417 (opens in new tab) Neuroplasticity Glutamatergic Autism spectrum disorder Therapeutic approach +2

Substance use predictors of arrest and self-reported criminal behavior in the United States: The role of psychedelics and rarely used drugs

Journal of Psychopharmacology April 16, 2026 Jesse J. Norris 1 citation

Background: Little research investigates the role of rarely used drugs in criminal offending. Moreover, given research suggesting that psychedelics reduce criminal offending, more research is needed to further document connections between psychedelics and crime. Aim: This study examines the role of rarely used drugs in criminal behavior and extends previous research on psychedelics by...

DOI: 10.1177/02698811261436577 (opens in new tab) MDMA Substance use Criminal behavior Hallucinogen +5

Blinding Integrity in Psychedelic Randomized Clinical Trials

JAMA Psychiatry April 15, 2026 Diana Orsini, Sabrina Wong, Sara Di Luch et al. 4 citations

Importance: Psychedelic drugs possess acute psychoactive effects that can compromise blinding integrity in randomized clinical trials (RCTs). Functional unblinding, when participants or raters correctly identify treatment allocation based on subjective effects, may bias outcomes through expectancy effects, challenging the validity of efficacy estimates and regulatory acceptance. Objective: To...

DOI: 10.1001/jamapsychiatry.2026.0255 (opens in new tab) Blinding Randomized controlled trial Clinical trial Meta-analysis +4

The Use of Psychedelics in the Treatment of Adult ADHD: A Systematic and Mechanistic Review.

International Journal of Molecular Sciences April 12, 2026 James Chmiel, Agnieszka Malinowska, Donata Kurpas

Interest in classical psychedelics as potential treatments for ADHD has grown alongside broader psychiatric psychedelic research, but ADHD-specific evidence remains limited. This systematic review examined prospective and experimental studies on whether classical psychedelics, including microdosing-like use and retreat-based exposure, are associated with changes in adult ADHD symptoms and...

DOI: 10.3390/ijms27083453 (opens in new tab) Full text (opens in new tab) ADHD Neurodevelopmental disorders Pharmacotherapy Psychedelics

Hallucinogenic Therapy in Alzheimer's Disease targeting Mitochondria-Associated Membranes.

Neuroscience April 6, 2026 Fernando Minauro-Sanmiguel, Hector Vargas-Perez

Mitochondrial dysfunction is increasingly recognized as a central driver of Alzheimer's disease (AD), contributing to neuroinflammation, synaptic failure, and energy collapse.Emerging preclinical evidence suggests that classic hallucinogens, such as psilocybin, lysergic acid diethylamide (LSD), N,N-dimethyltryptamine (DMT), mescaline, may restore mitochondrial integrity by activating Serotonin...

Classic psychedelics in obsessive–compulsive disorder: a circuit-based framework

Nature Mental Health April 1, 2026 Saif S. Ali, Robin Carhart-Harris, Karl G. Sieg

Obsessive–compulsive disorder (OCD) is a psychiatric condition with high rates of treatment resistance. Emerging neuroimaging evidence implicates dysfunction in large-scale brain networks, particularly the cortico–striatal–thalamo–cortical (CSTC) circuit, default mode network (DMN) and salience network (SN). Lysergic acid diethylamide (LSD) and psilocybin induce acute dysregulation of the DMN...

Clinical Characteristics of Emergency Visits Related to Recreational Psychedelic Use.

Community Mental Health Journal April 1, 2026 Kush V. Bhatt, Joseph Friedman, Lindsay L Benster et al.

Recreational psychedelic use is increasing, yet data on adverse events remains limited. This study characterized emergency department (ED) visits associated with recreational psychedelic use at UC San Diego Medical Center. We conducted a retrospective chart review of ED encounters (2010–2023). Cases were identified using ICD-10 hallucinogen-related codes and confirmed through manual review....

DOI: 10.1007/s10597-026-01620-x (opens in new tab) Full text (opens in new tab) Psychedelic Emergency department Hallucinogen Substance use

An international mega-analysis of psychedelic drug effects on brain circuit function

Nature Medicine April 1, 2026 Manesh Girn, Manoj K. Doss, Leor Roseman et al. 8 citations

Psychedelic drugs are re-emerging as promising scientific and clinical tools. However, despite a rapidly expanding literature on their therapeutic value, the neural mechanisms underlying psychedelic effects remain unclear. Resting-state functional magnetic resonance imaging studies of acute psychedelic effects, conducted independently by several research groups, have so far yielded fragmented...

Mystical dynamics: renewal, luminous light, and ego disintegration as key features associated with mystical oneness—a psychometric analysis using the PES100 in controlled psychedelic studies

Religion, Brain & Behavior March 31, 2026 Kurt Stocker, Matthias Hartmann, Frederick S. Barrett et al.

Mystical dynamics—the notion that mystical oneness may unfold involving ego disintegration, renewal, and luminous light—has been discussed anecdotally by psychedelic researchers and therapists but has not yet been empirically examined in controlled settings. This study investigated the occurrence and dose-dependency of mystical dynamics in healthy participants after administration of...

DOI: 10.1080/2153599x.2026.2635353 (opens in new tab) Mysticism Psychometrics Key lock Psychometric testing +4